
Abingworth appoints MVM's Muralidhar

Specialist life sciences investment firm Abingworth has appointed Bali Muralidhar, formerly of MVM Partners, as partner in its London office.
Muralidhar will work with the team in London, Boston and Melo Park to source and evaluate new investment opportunities, as well as supporting existing investments.
Prior to joining Abingworth, Muralidhar was a senior partner at MVM, another London- and Boston-based life sciences investor. The GP is currently raising capital for MVM V, with a target of £300m.
Earlier in his career, Muralidhar worked for Bain Capital in the healthcare deal team; prior to that, he practiced as a general surgeon at John Radcliffe Hospital and Addenbrooke's Hospital, in Oxford and Cambridge respectively.
Abingworth closed its seventh fund, Abingworth Bioventures VII, on $300m in July 2018.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater